TABLE 4.
The ability of each SNP to predict changes in fasting and 2-h glucose concentrations over a 10-year follow-up period (n = 4,059)
| SNP | Nearest gene (s) | Effect allele (frequency) | Change in fasting glucose (mmol/l) |
Change in 2-h glucose (mmol/l) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Effect (SE)* | P* | Corrected P* | Effect (SE)† | P† | Corrected P† | Effect‡ (SE)‡ | P‡ | Corrected P‡ | |||
| rs4607517 | GCK | A (0.15) | 0.057 (0.022) | 0.010 | 0.17 | 0.015 (0.048) | 0.750 | 0.99 | −0.029 (0.046) | 0.528 | 0.99 |
| rs10885122 | ADRA2A | G (0.89) | 0.062 (0.026) | 0.017 | 0.27 | 0.042 (0.055) | 0.451 | 0.99 | −0.004 (0.052) | 0.945 | 0.99 |
| rs2191349 | DGKB-TMEM195 | T (0.51) | 0.037 (0.016) | 0.020 | 0.31 | −0.007 (0.034) | 0.849 | 0.99 | −0.030 (0.033) | 0.362 | 0.99 |
| rs560887 | G6PC2 | C (0.71) | 0.038 (0.017) | 0.031 | 0.43 | 0.001 (0.038) | 0.970 | 0.99 | −0.027 (0.036) | 0.454 | 0.99 |
| rs10830963 | MTNR1B | G (0.28) | 0.034 (0.018) | 0.059 | 0.77 | −0.092 (0.039) | 0.018 | 0.29 | −0.131 (0.037) | 4.0 × 10−4 | 6.5 × 10−3 |
| rs780094 | GCKR | C (0.71) | −0.030 (0.018) | 0.088 | 0.99 | −0.065 (0.038) | 0.085 | 0.99 | −0.052 (0.036) | 0.144 | 0.99 |
| rs7903146 | TCF7L2 | T (0.20) | 0.028 (0.020) | 0.159 | 0.99 | 0.044 (0.043) | 0.307 | 0.99 | 0.027 (0.041) | 0.515 | 0.99 |
| rs11071657 | C2CD4B | A (0.60) | 0.021 (0.016) | 0.193 | 0.99 | −0.028 (0.036) | 0.426 | 0.99 | −0.046 (0.034) | 0.174 | 0.99 |
| rs11708067 | ADCY5 | A (0.79) | 0.014 (0.020) | 0.488 | 0.99 | 0.100 (0.043) | 0.020 | 0.30 | 0.092 (0.040) | 0.023 | 0.34 |
| rs11920090 | SLC2A2 | T (0.86) | 0.016 (0.024) | 0.501 | 0.99 | 0.006 (0.051) | 0.906 | 0.99 | −0.002 (0.050) | 0.959 | 0.99 |
| rs11605924 | CRY2 | A (0.50) | 0.011 (0.016) | 0.503 | 0.99 | −0.026 (0.034) | 0.453 | 0.99 | −0.032 (0.033) | 0.322 | 0.99 |
| rs340874 | PROX1 | C (0.53) | 0.010 (0.016) | 0.534 | 0.99 | −0.037 (0.034) | 0.278 | 0.99 | −0.057 (0.032) | 0.078 | 0.99 |
| rs174550 | FADS1 | T (0.66) | −0.007 (0.017) | 0.668 | 0.99 | −0.006 (0.037) | 0.873 | 0.99 | 0.002 (0.035) | 0.947 | 0.99 |
| rs7944584 | MADD | A (0.76) | 0.007 (0.019) | 0.723 | 0.99 | −0.072 (0.042) | 0.085 | 0.99 | −0.081 (0.040) | 0.043 | 0.60 |
| rs13266634 | SLC30A8 | C (0.70) | 0.006 (0.017) | 0.731 | 0.99 | 0.040 (0.037) | 0.278 | 0.99 | 0.024 (0.035) | 0.494 | 0.99 |
| rs7034200 | GLIS3 | A (0.43) | 0.005 (0.016) | 0.757 | 0.99 | −0.002 (0.035) | 0.948 | 0.99 | −0.003 (0.033) | 0.926 | 0.99 |
SNPs are ranked by P value of the per-allele effect on change in fasting glucose concentrations. Multiple testing was corrected for using the Holm procedure (29). All genotypes are located on the plus strand and are coded according to HapMap CEU (phase II + III), release 27, National Center for Biotechnology Information build 36. Two-hour glucose concentrations were measured by an oral glucose tolerance test in accordance with the World Health Organization guidelines (21).
*Adjusted for baseline age, sex, fasting glycemia, fasting times at baseline and follow-up, and follow-up time.
‡Adjusted for baseline age, sex, 2-h glucose concentrations, fasting times at baseline and follow-up, and follow-up time.
†Adjusted for baseline age, sex, 2-h glucose concentrations, fasting times at baseline and follow-up, follow-up time and fasting glucose concentrations at baseline and follow-up.